BGXX (Bright Green) Investments And Advances : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Bright Green Investments And Advances?

Bright Green's Investments And Advances for the quarter that ended in Jun. 2024 was $0.00 Mil.

Bright Green's quarterly Investments And Advances declined from Dec. 2023 ($0.73 Mil) to Mar. 2024 ($0.00 Mil) but then stayed the same from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil).

Bright Green's annual Investments And Advances increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($3.99 Mil) but then declined from Dec. 2022 ($3.99 Mil) to Dec. 2023 ($0.73 Mil).

Bright Green Investments And Advances Historical Data

The historical data trend for Bright Green's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Green Investments And Advances Chart

Bright Green Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Investments And Advances

3.99

0.73

Bright Green Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Investments And Advances	Get a 7-Day Free Trial										3.99	3.81	0.73	-	-

Bright Green Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Bright Green Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bright Green Corp (OTCPK:BGXX) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

N/A

Address

1033 George Hanosh Boulevard, Grants, NM, USA, 87020

Website

https://www.brightgreen.us

Bright Green Corp is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured for research and pharmaceutical applications, as well as being an active ingredient in consumer-based solutions. The company plans to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).

Executives

Saleem Elmasri	officer: Chief Financial Officer	450 PARK AVE SOUTH, 3RD FLOOR, NEW YORK NY 10016
Lynn Stockwell	director, 10 percent owner	401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Gurvinder Singh	officer: Chief Executive Officer	1033 GEORGE HANOSH BOULEVARD, GRANTS NM 87020
Seamus Mcauley	officer: Chief Executive Officer	1033 GEORGE HANOSH BOULEVARD, GRANTS NM 87020
Edward A. Robinson	director, officer: Chief Executive Officer	401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Alfie Morgan	director	401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Dean Vallore	director	401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Terry Rafih	director, 10 percent owner	401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Robert Arnone	director	401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
E. Mailloux Enterprises, Inc.	10 percent owner	3129 MARENTETTE AVENUE, UNIT 2, WINDSOR A6 N8X 4G1